Lupin Limited, a leading pharmaceutical company, has partnered with Honeywell to integrate the Solstice Air propellant into its next-generation inhalers for respiratory care. This collaboration aims to enhance treatment for patients with asthma and chronic obstructive pulmonary disease (COPD) while reducing the environmental impact of inhaler technologies. Solstice Air is a non-flammable propellant that offers a more environmentally friendly alternative to traditional hydrofluorocarbon (HFC)-based options, decreasing greenhouse gas emissions by up to 99.9%.
Lupin plans to become the first pharmaceutical company in India to use Solstice Air as a large-scale propellant in pressurized metered-dose inhalers (pMDIs). This move aligns with the company’s commitment to minimizing its carbon footprint while delivering effective care to patients. Vinita Gupta, CEO of Lupin, emphasized the company’s dedication to providing high-quality treatments while ensuring a healthier and more sustainable future for patients and communities globally.
The partnership with Honeywell reflects Lupin’s focus on advancing sustainable healthcare solutions. Ashish Modi, President of Honeywell India, highlighted the importance of Solstice Air in delivering safe and effective treatments while minimizing harmful greenhouse gas emissions. The companies are currently negotiating the details of the partnership, with the goal of finalizing the terms soon.
Lupin Limited is a major player in the global pharmaceutical industry, with a strong presence in therapy areas such as respiratory care, cardiovascular, and anti-diabetic treatments. The company operates 15 manufacturing facilities and seven research centers globally, employing over 23,000 professionals. Honeywell, a global leader in technology and innovation, is committed to addressing complex challenges through its cutting-edge solutions, enhancing safety, security, and sustainability worldwide.
The integration of Solstice Air into Lupin’s inhalers is expected to significantly reduce the environmental impact of respiratory treatments. With this partnership, Lupin and Honeywell are taking a major step towards advancing sustainable healthcare solutions and reducing carbon emissions. The collaboration demonstrates the companies’ shared commitment to providing effective treatments while promoting environmentally responsible practices. By adopting innovative technologies like Solstice Air, Lupin is poised to make a positive impact on the environment and improve patient health outcomes.